2025 has seen a wave of positive anti-fibrosis advances. From Agomab’s Phase 2a results in fibrostenosing Crohn’s, to Boehringer’s Phase 3 IPF data, it’s clear the antifibrotic drug development landscape is undergoing a seismic shift. That’s why this year’s Antifibrotic Drug Development Summit is THE place to be this November. Learn from the industry’s experts at the forefront of fibrosis research, and make unmatched connections with 80+ leaders from Pfizer, Eli Lilly, Novartis, Takeda and more! Access this year’s lineup of speakers
Join us to:
- Unlock novel targets with advances in single-cell and spatial omics, immune-stromal interactions, and cross-tissue mechanisms
- Strengthen translational confidence with precision-cut tissue slices, 3D models, and AI-driven biomarker strategies to bridge the gap between preclinical promise and clinical success
- Design winning clinical programs with lessons from recent Phase 2 data
- Navigate the evolving landscape with expert perspectives on combination therapies, GLP-1 competition, and investor priorities
Register today to take advantage of our early bird rates and group savings! Secure my spot
Event Details:
Event Name: 9th Antifibrotic Drug Development Summit
Event Date: Nov 17-19, 2025
Event Venue: Boston, MA
Event Organizers: Hanson Wade
Contact Number (with country & area code): US: +1 617 455 4188
Email: info@hansonwade.com
URL: https://ter.li/verug8
Boston , MA, USA